About PTC Therapeutics, Inc.
https://www.ptcbio.comPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
CEO
Matthew B. Klein F.A.C.S.,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 209
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Jefferies
Buy
B of A Securities
Buy
Truist Securities
Buy
UBS
Buy
Baird
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 14
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:8.29M
Value:$640.66M
BLACKROCK INC.
Shares:7.77M
Value:$600.71M
RTW INVESTMENTS, LP
Shares:7.75M
Value:$598.72M
Summary
Showing Top 3 of 362
About PTC Therapeutics, Inc.
https://www.ptcbio.comPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $211.01M ▲ | $92.05M ▼ | $15.9M ▲ | 7.53% ▲ | $0.2 ▲ | $20.63M ▲ |
| Q2-2025 | $178.88M ▼ | $202.41M ▲ | $-64.85M ▼ | -36.25% ▼ | $-0.83 ▼ | $-33.11M ▼ |
| Q1-2025 | $1.18B ▲ | $193.01M ▼ | $866.56M ▲ | 73.68% ▲ | $11.09 ▲ | $971.14M ▲ |
| Q4-2024 | $213.17M ▲ | $359.28M ▲ | $-65.89M ▲ | -30.91% ▲ | $-0.85 ▲ | $-46.88M ▲ |
| Q3-2024 | $196.79M | $240.45M | $-106.65M | -54.2% | $-1.39 | $-49.9M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.71B ▼ | $2.64B ▲ | $2.8B ▼ | $-155.76M ▲ |
| Q2-2025 | $1.99B ▼ | $2.63B ▼ | $2.84B ▼ | $-206.55M ▼ |
| Q1-2025 | $2.03B ▲ | $2.66B ▲ | $2.84B ▲ | $-185.76M ▲ |
| Q4-2024 | $1.14B ▲ | $1.71B ▼ | $2.8B ▼ | $-1.1B ▼ |
| Q3-2024 | $1.01B | $1.84B | $2.9B | $-1.05B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $15.9M ▲ | $-66.3M ▼ | $-289.62M ▲ | $15.22M ▲ | $-344.77M ▲ | $-69.75M ▼ |
| Q2-2025 | $-64.85M ▼ | $-58.33M ▼ | $-422.01M ▼ | $3.96M ▼ | $-462.79M ▼ | $-62.33M ▼ |
| Q1-2025 | $866.56M ▲ | $870.1M ▲ | $-184.36M ▼ | $9.41M ▼ | $700.55M ▲ | $867.57M ▲ |
| Q4-2024 | $-65.89M ▲ | $-30M ▲ | $267.71M ▲ | $26.47M ▲ | $255.53M ▲ | $-36.5M ▲ |
| Q3-2024 | $-106.65M | $-76.99M | $-42.67M | $-17.63M | $-128.75M | $-87.77M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration and License Revenue | $0 ▲ | $990.00M ▲ | $0 ▼ | $10.00M ▲ |
 Product | $470.00M ▲ | $150.00M ▼ | $120.00M ▼ | $130.00M ▲ |
 Royalty | $140.00M ▲ | $40.00M ▼ | $60.00M ▲ | $70.00M ▲ |
 Manufacturing | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2023 | Q3-2023 | Q3-2025 | Q2-2025 |
|---|---|---|---|---|
 NonUS | $120.00M ▲ | $80.00M ▼ | $70.00M ▼ | $80.00M ▲ |
 UNITED STATES | $340.00M ▲ | $70.00M ▼ | $60.00M ▼ | $40.00M ▼ |
CEO
Matthew B. Klein F.A.C.S.,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 209
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Jefferies
Buy
B of A Securities
Buy
Truist Securities
Buy
UBS
Buy
Baird
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 14
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:8.29M
Value:$640.66M
BLACKROCK INC.
Shares:7.77M
Value:$600.71M
RTW INVESTMENTS, LP
Shares:7.75M
Value:$598.72M
Summary
Showing Top 3 of 362